These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 37409790)

  • 41. Practice Patterns and Barriers in Botulinum Toxin Injection for the Treatment of Voice Disorders.
    McGarey PO; Simpson CB; Daniero JJ
    J Voice; 2022 Jan; 36(1):113-118. PubMed ID: 32467003
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Alternating unilateral botulinum toxin type A (BOTOX) injections for spasmodic dysphonia.
    Koriwchak MJ; Netterville JL; Snowden T; Courey M; Ossoff RH
    Laryngoscope; 1996 Dec; 106(12 Pt 1):1476-81. PubMed ID: 8948606
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Spasmodic dysphonia: a seven-year audit of dose titration and demographics in the Indian population.
    Nerurkar NK; Banu TP
    J Laryngol Otol; 2014 Jul; 128(7):649-53. PubMed ID: 24999662
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Unilateral versus bilateral thyroarytenoid Botulinum toxin injections in adductor spasmodic dysphonia: a prospective study.
    Upile T; Elmiyeh B; Jerjes W; Prasad V; Kafas P; Abiola J; Youl B; Epstein R; Hopper C; Sudhoff H; Rubin J
    Head Face Med; 2009 Oct; 5():20. PubMed ID: 19852852
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Treatment of spasmodic dysphonia with botulinum toxin].
    Klap P; Marion MH; Perrin A; Fresnel-Elbaz E
    Ann Otolaryngol Chir Cervicofac; 1991; 108(8):477-82; discussion 482-3. PubMed ID: 1789624
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Impact of an Upper Respiratory Tract Infection on Botulinum Toxin Efficacy in Spasmodic Dysphonia Patients.
    Kirke DN; Kaye R; Blitzer A
    Laryngoscope; 2020 Jul; 130(7):1746-1749. PubMed ID: 31508822
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Patient Experience Contributing to Outcomes of Laryngeal Botulinum Toxin Injection.
    Rutt A; Kennelly KD; Martinez-Paredes JF
    J Voice; 2022 Mar; 36(2):272-276. PubMed ID: 32553551
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Laryngeal Botulinum Toxin Injection: Can It Be a Cause of Obstructive Sleep Apnea as an Adverse Effect?
    Oktay Arslan B; Demirhan E; Uçar Hoşgör ZZ
    J Voice; 2022 Jan; 36(1):119-122. PubMed ID: 32482493
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Voice analysis in adductor spasmodic dysphonia: Objective diagnosis and response to botulinum toxin.
    Suppa A; Asci F; Saggio G; Marsili L; Casali D; Zarezadeh Z; Ruoppolo G; Berardelli A; Costantini G
    Parkinsonism Relat Disord; 2020 Apr; 73():23-30. PubMed ID: 32222482
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A comparison of the efficacy of unilateral versus bilateral botulinum toxin injections in the treatment of adductor spasmodic dysphonia.
    Maloney AP; Morrison MD
    J Otolaryngol; 1994 Jun; 23(3):160-4. PubMed ID: 8064952
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Analysis of phonosurgical methods of treatment in spasmodic dysphonia].
    Kosztyła-Hojna B; Berger G; Zdrojkowski M
    Pol Merkur Lekarski; 2017 Feb; 42(248):90-92. PubMed ID: 28258685
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical experience with patients with spasmodic dysphonia and primary Meige syndrome.
    Pedrero-Escalas MF; García-López I; Santiago-Pérez S; Vivancos F; Gavilán J
    Acta Otorrinolaringol Esp (Engl Ed); 2019; 70(1):1-5. PubMed ID: 29716720
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Unilateral versus bilateral injections of botulinum toxin in patients with adductor spasmodic dysphonia.
    Bielamowicz S; Stager SV; Badillo A; Godlewski A
    J Voice; 2002 Mar; 16(1):117-23. PubMed ID: 12002878
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Botulinum toxin treatment of adductor spasmodic dysphonia: longitudinal functional outcomes.
    Novakovic D; Waters HH; D'Elia JB; Blitzer A
    Laryngoscope; 2011 Mar; 121(3):606-12. PubMed ID: 21298641
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tridimensional assessment of adductor spasmodic dysphonia pre- and post-treatment with Botulinum toxin.
    Dejonckere PH; Neumann KJ; Moerman MB; Martens JP; Giordano A; Manfredi C
    Eur Arch Otorhinolaryngol; 2012 Apr; 269(4):1195-203. PubMed ID: 22210475
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharyngeal Dystonia Mimicking Spasmodic Dysphonia.
    Shi LL; Simpson CB; Hapner ER; Jinnah HA; Johns MM
    J Voice; 2018 Mar; 32(2):234-238. PubMed ID: 28651822
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bilateral Posterior Cricoarytenoid Myoneurectomy for Abductor Spasmodic Dysphonia.
    Benito DA; Ferster APO; Sataloff RT
    J Voice; 2020 Jan; 34(1):127-129. PubMed ID: 30174222
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Safety of simultaneous bilateral botulinum toxin injections for abductor spasmodic dysphonia.
    Stong BC; DelGaudio JM; Hapner ER; Johns MM
    Arch Otolaryngol Head Neck Surg; 2005 Sep; 131(9):793-5. PubMed ID: 16172357
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The swallowing side effects of botulinum toxin type A injection in spasmodic dysphonia.
    Holzer SE; Ludlow CL
    Laryngoscope; 1996 Jan; 106(1 Pt 1):86-92. PubMed ID: 8544635
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Botulinum toxin injection for treatment of spasmodic dysphonia: experience at Srinagarind Hospital.
    Srirompotong S; Saeseow P; Taweesaengsuksakul R; Kharmwan S; Srirompotong S
    J Med Assoc Thai; 2006 Dec; 89(12):2077-80. PubMed ID: 17214059
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.